The presentation of interim data from the FASCINATE-2 Phase 2b trial of denifanstat in NASH at the EASL Congress 2023 is a significant event for Sagimet Biosciences. Positive results may lead to increased investor interest and a potential rise in the stock price, while negative results may have the opposite effect. The news is highly relevant and important for investors in SGMT, and the confidence in the analysis is based on the direct impact of the trial results on the company's prospects.